Drug Information

Drug General Information
Drug ID
D0X0RI
Former ID
DAP000505
Drug Name
Mexiletine
Synonyms
Mexiletene; Mexiletina; Mexiletinum; Mexilitine; Mexityl; Mexiletine HCL; KO1173; KO-1173; KOE-1173; Mexiletina [INN-Spanish]; Mexiletine (INN); Mexiletine [INN:BAN]; Mexiletinum [INN-Latin]; Mexitil (TN); (+-)-1-(2,6-dimethylphenoxy)propan-2-amine; (2RS)-1-(2,6-dimethylphenoxy)-2-aminopropane; 1-(2',6'-Dimethylphenoxy)-2-aminopropane; 1-(2,6-Dimethylphenoxy)-2-propanamine; 1-(2,6-dimethylphenoxy)propan-2-amine; 1-Methyl-2-(2,6-xylyloxy)ethylamine; 1-methyl-2-(2,6-xylyloxy)ethanamine; 2-(2-Aminopropoxy)-1,3-DiMethyl-Benzene Hydrochloride; 2-(2-aminopropoxy)-1,3-dimethylbenzene
Drug Type
Small molecular drug
Indication Ventricular tachycardia; Symptomatic premature ventricular beats; Ventricular fibrillation [ICD10:I47.2] Approved [551871]
Therapeutic Class
Antiarrhythmic Agents
Company
Boehringer Ingelheim
Structure
Download
2D MOL

3D MOL
Formula
C11H17NO
InChI
InChI=1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H3
InChIKey
VLPIATFUUWWMKC-UHFFFAOYSA-N
CAS Number
CAS 31828-71-4
PubChem Compound ID
4178
PubChem Substance ID
9429, 3249367, 5025145, 7979981, 8152616, 10518377, 11336009, 11361248, 11364496, 11367058, 11369620, 11371574, 11374409, 11377782, 11462220, 11466269, 11467389, 11485977, 11490543, 11492610, 11495416, 14772717, 29223284, 46505491, 47216821, 47291179, 47365237, 47662331, 47885459, 48110495, 48110496, 48259281, 49698949, 49969305, 50111148, 50111149, 50468461, 57322180, 85788456, 90341048, 92250812, 92729782, 96024903, 99233247, 103178542, 104010844, 104222091, 104305656, 117396020, 117396021
SuperDrug ATC ID
C01BB02
SuperDrug CAS ID
cas=031828714
Target and Pathway
Target(s) Sodium channel protein type 5 subunit alpha Target Info Blocker [535117]
KEGG Pathway Adrenergic signaling in cardiomyocytes
PathWhiz Pathway Muscle/Heart Contraction
Reactome Interaction between L1 and Ankyrins
WikiPathways SIDS Susceptibility Pathways
Cardiac Progenitor Differentiation
References
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 535117Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.